Kojic acid in skincare — what it actually does, and where it sits in a brightening protocol.

Kojic acid is a chelating agent produced as a by-product of fungal fermentation — specifically Aspergillus oryzae, the fungus used to produce sake, soy sauce, and miso. The name derives from the Japanese word for the mould. It was identified as a tyrosinase inhibitor in the 1980s and has since become one of the more widely used brightening actives in cosmetic formulation.

Its mechanism is distinct from alpha-arbutin and niacinamide, which is why it appears frequently in combination brightening products. But its instability and sensitisation potential are real constraints that matter in practice.

Mechanism

Kojic acid inhibits tyrosinase through copper chelation. Tyrosinase is a copper-containing enzyme; the copper at its active site is essential to its catalytic function. Kojic acid chelates — binds to — these copper ions, physically blocking the enzymatic reaction that converts tyrosine into DOPA and ultimately into melanin. Without that conversion, melanin synthesis is suppressed at the source.

This is a mechanistically different point of intervention from alpha-arbutin (which inhibits tyrosinase through competitive binding to the substrate site rather than copper chelation) and from niacinamide (which operates downstream, inhibiting melanosome transfer). All three address the same clinical outcome — reduced visible pigmentation — through different biochemical points of attack.

Evidence

The clinical evidence for kojic acid is consistent but more limited than for alpha-arbutin or hydroquinone. Studies at concentrations of 1–2% show statistically significant reduction in melanin index and improvement in measures of hyperpigmentation compared to vehicle control, with effects accumulating over 8–12 weeks of regular use.

Several studies have compared kojic acid to 4% hydroquinone and found comparable results, which is clinically meaningful given hydroquinone's status as the reference standard for hyperpigmentation treatment. The comparison is concentration-dependent, however — the studies use the effective concentration for each agent, and kojic acid at 1–2% is near the top of its practical cosmetic range, while hydroquinone at 4% is the standard therapeutic dose.

The evidence for combinations is generally favourable. Kojic acid combined with glycolic acid or niacinamide in published studies consistently outperforms either agent alone, supporting the rationale for multi-mechanism brightening protocols.

Stability

Kojic acid's primary formulation challenge is stability. It oxidises readily in the presence of air, heat, and light, turning the product brown. That browning is not purely cosmetic — oxidised kojic acid has reduced tyrosinase-inhibiting activity. A kojic acid product that has discoloured significantly has likely degraded.

This instability is the main reason for kojic acid dipalmitate, a more lipid-soluble ester form that is more chemically stable. Kojic acid dipalmitate is absorbed through the skin and converted to kojic acid after absorption, but the available evidence on its bioequivalence to kojic acid — whether the same concentration of the ester produces the same clinical effect — is less robust than the evidence for the parent compound. Not all kojic acid ester products perform equivalently to the acid.

Product packaging matters more for kojic acid than for most other actives. Airless pumps and opaque containers meaningfully extend stability compared to open jars or clear bottles.

Sensitisation potential

Kojic acid has a higher rate of contact sensitisation than alpha-arbutin or niacinamide. Studies of patch testing in dermatology practices find kojic acid among the more frequently positive cosmetic ingredients, with sensitisation rates in the range of a few percent in screened patients — low in absolute terms, but higher than most other commonly used brightening actives.

The practical implication is not that kojic acid should be avoided. It is that people with a history of contact dermatitis, reactive skin, or existing sensitisation to cosmetic ingredients should introduce it with more caution than they would a gentler alternative, and should patch-test before committing to regular use.

Sensitisation, once established, is typically permanent — the immune response to a sensitiser is not a transient irritation but an acquired hypersensitivity. This asymmetry — manageable risk of sensitisation at first use, permanent hypersensitivity if it occurs — is worth considering when choosing between kojic acid and the more tolerable alternatives.

How to use it

At 1–2% in a leave-on serum or treatment product, applied once or twice daily to areas of hyperpigmentation, is the standard approach. Results require consistent use over 8–12 weeks. The concentration range is narrow — below 1% the clinical effect becomes unreliable; above 2–3% the tolerability concern and sensitisation risk increase without a proportional benefit.

Evening use is practical to avoid potential photo-degradation of the product itself (sunlight exposure of the bottle accelerates oxidation), but azelaic acid does not increase photosensitivity in the way AHAs do, so daytime use is not contraindicated.

SPF is important for the same reason it matters with all brightening actives: UV exposure continuously stimulates the melanin production that the active is working to suppress.

The Lux & Glo position

Kojic acid is a legitimate brightening active with meaningful clinical backing and a distinct mechanism. Its instability and relatively higher sensitisation potential compared to alpha-arbutin make formulation quality and product freshness important variables — more so than with most other actives.

For skin managing persistent hyperpigmentation that has not responded adequately to niacinamide and alpha-arbutin, kojic acid used in combination is a logical next consideration. It is not a first-choice active for sensitive skin or skin with a history of contact reactivity — in those situations, alpha-arbutin or azelaic acid are more forgiving starting points.

The core ritual addresses the foundation. Brightening actives — kojic acid included — belong in the treatment layer for skin with specific concerns and sufficient barrier health to tolerate them.